A Prospective Study to Evaluate Effectiveness of Upadacitinib in Moderate to Severe AD with Prurigo Nodules in the Real World in Japa
Not Applicable
- Conditions
- atopic dermatitis
- Registration Number
- JPRN-UMIN000048463
- Lead Sponsor
- AbbVie GK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who had prior treatment with Upadacitinib 2.Patients who have contraindications to Upadacitinib 3. Patients who have chronic pruritus resulting from another condition (e.g.,neuropathic disorders) than AD, prurigo nodules 4. Patients who have prurigo nodules caused by medication, metal allergy, infection, insect bite 5. Patients who are currently participating in interventional research or participated within 30 days (not including another post-marketing observational study, or registry participation).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method